Catalent announced yesterday the acquisition of a biologics development and manufacturing facility. Owned by Vaccine Manufacturing and Innovation Centre UK Limited , the new facility is located near Oxford, UK, on the Harwell Science and Innovation Campus, which is already home to more than 40 life science companies. Catalent plans to invest $160 million to complete the building and set up high-tech equipment for the development and production of biological therapies and vaccines, including mRNA and proteins.
Mike Riley, President of Catalent Biotherapeutics said, “This acquisition allows Catalent to collaborate with the rich academic and biomedical science community centered in Oxford, with its world-class talent, and will result in a facility that offers opportunities to turn innovation into real treatments for patients across the UK, Europe and beyond. Our priority is to complete construction as soon as possible to be in a position to begin customer programs in 2022. We will then integrate its capabilities into our existing network of biologics facilities across Europe to provide a flexible range of manufacturing, technology and development solutions for the pipeline of thousands of development programs currently underway.”
This acquisition is part of the investment program undertaken by Catalent, which notably recently completed a $30M project for its French facility. The site, located in Limoges, is now a Center of Excellence for biopharmaceutical development, as well as for product filling and packaging services. Totally modernized, it has an additional capacity for the development of small injectable molecules. A filling line that can process different types of containers such as vials or syringes completes the investment.